Vertex Pharmaceuticals Incorporated (ETR: VX1)
Germany
· Delayed Price · Currency is EUR | Market Cap | 98.22B |
| Revenue (ttm) | 9.53B |
| Net Income (ttm) | -430.19M |
| Shares Out | n/a |
| EPS (ttm) | -1.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 435 |
| Open | 382.80 |
| Previous Close | 373.65 |
| Day's Range | 371.55 - 382.80 |
| 52-Week Range | 353.40 - 489.20 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 6, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underl... [Read more]
Financial Performance
In 2023, Vertex Pharmaceuticals's revenue was $9.87 billion, an increase of 10.51% compared to the previous year's $8.93 billion. Earnings were $3.62 billion, an increase of 8.96%.
Financial numbers in USD Financial StatementsNews
Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
BOSTON, MA / ACCESSWIRE / December 20, 2024 / Block & Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq:VRTX) for potential securities law violations. Investors who have lost money in their...
Oppenheimer Downgrades Vertex Pharmaceuticals (VRTX) After Study Results
Oppenheimer Downgrades Vertex Pharmaceuticals (VRTX) After Study Results
Vertex downgraded to perform by Oppenheimer
Financial writer downgrades Vertex (VRTX) based on Phase 2 data for suzetrigrine, citing uncertain benefit/risk profile in LSR treatment.
Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot
The CNBC 'Halftime Report' Investment Committee weighs in on 'Stocks on the Move' and their picks.
Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot
The CNBC 'Halftime Report' Investment Committee weighs in on 'Stocks on the Move' and their picks.
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
On Thursday, Vertex Pharmaceuticals Incorporated VRTX announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower bac...
Vertex Pharmaceuticals Faces Legal Scrutiny Over Clinical Trial Results
Vertex Pharmaceuticals Faces Legal Scrutiny Over Clinical Trial Results
Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
Block & Leviton is investigating Vertex Pharmaceuticals (Nasdaq: VRTX) for potential securities fraud. Investors who lost money should contact the firm.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1763769061-1faa7bf1d32e425a96a3857c3a98ef93.jpg)
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.
Cramer's Stop Trading: Vertex Pharmaceuticals
CNBC's Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals.
Cramers Stop Trading: Vertex Pharmaceuticals
CNBCs Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals.
Tech and auto stocks surge: Semiconductor sector rebounds with Tesla leading gains
Sector Overview Today’s US stock market is witnessing a significant upswing in the technology and automotive sectors, driven by gains in leading companies. Notably, the semiconductor sector is rebound...
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.
Vertex Pharmaceuticals Inc (VRTX) Announces Positive Phase 2 Results for Suzetrigine in Painful ...
Vertex Pharmaceuticals Inc (VRTX) Announces Positive Phase 2 Results for Suzetrigine in Painful Lumbosacral Radiculopathy
Vertex’s non-opioid drug succeeds in back pain trial
Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls due to placebo response.
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal...
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Stifel ra...
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of VRTX stock now.
Wall Street is turning bullish on this biotech. How to play it with options
Nishant Pant breaks down a bull call spread trade in Vertex Pharmaceuticals.
Jefferies Upgrades Vertex Pharmaceuticals (VRTX) to 'Buy' Amid Strong R&D Prospects
Jefferies Upgrades Vertex Pharmaceuticals (VRTX) to 'Buy' Amid Strong R&D Prospects
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), citing the company’s robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billio...
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies has upgraded Vertex Pharmaceuticals Inc. VRTX, citing the company's robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportuni...
Vertex reports positive long-term data for Casgevy
Vertex Pharmaceuticals (VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business update on the product. Read more here.
Vertex Pharmaceuticals Unveils Promising Long-Term Data for CASGEVY⢠Gene Therapy
Vertex Pharmaceuticals Unveils Promising Long-Term Data for CASGEVY⢠Gene Therapy
Vertex Presents Positive Long-Term Data On CASGEVY (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) o...